Bayer's Settlement Strategy Gains a Judicial Ally as a July Hearing and Supreme Court Decision Draw Near
20.06.2026 - 13:43:27 | boerse-global.de
Bayer emerged from a pivotal week with a clean procedural victory in the US Roundup litigation, the completion of a biotech acquisition, and a share price that clawed back above its 50-day moving average. The German conglomerate's stock closed at €37.81 on Friday, up 2.13% on the day and nearly 5% over the week, although data in the market also showed a close at precisely €37.80 — exactly on the 50-day line. The relative strength index at 55.8 points to a neutral technical picture with no overheating signals.
The most consequential development came on June 17, when US District Judge Henry E. Autrey of the Eastern District of Missouri ruled that the proposed $7.25 billion Roundup class-action settlement belongs before the Missouri State Court in St. Louis, not a federal bench. Autrey rejected arguments from a group of cancer victims who claimed a state court could not bind a nationwide class, and clarified that only Bayer as the defendant had the right to move the case to federal court. The decision effectively sidelines a different federal judge who had publicly criticised the deal. The case now returns to Judge Timothy Boyer in St. Louis, who had granted preliminary approval to the settlement in March. The final fairness hearing is scheduled for July 9, 2026. Objectors have already filed an appeal against Autrey's order.
Bayer has spent more than $10 billion to resolve Roundup claims to date, with roughly 65,000 cases still pending. The settlement proposed in February is designed to end nearly all remaining claims through a new class mechanism. Beyond the July hearing, a separate case before the US Supreme Court could reshape the litigation landscape entirely. Bayer is arguing that federal pesticide labelling requirements should preempt state-law failure-to-warn claims. A decision is expected by the end of July.
Should investors sell immediately? Or is it worth buying Bayer?
Alongside the legal calendar, Bayer closed its acquisition of Perfuse Therapeutics on June 17. The company paid $300 million upfront, with milestone payments that could lift the total consideration to $2.45 billion. The deal brings PER-001, an intravitreal implant for sustained drug release currently in Phase II trials for glaucoma and diabetic retinopathy — conditions affecting up to 80 million and roughly 146 million people worldwide, respectively. Bayer sees the candidate as a potential first-in-class disease-modifying therapy for both indications.
The legal relief, however, carries a heavy financial cost. Management expects legal outflows of around €5 billion in 2026, which could drag free cash flow to minus €2.5 billion. That burn rate is one reason the stock remains 24% below its February 2026 high of €49.93. On the valuation front, analysts are split. Jefferies pegs the sum-of-the-parts at €30 to €45, while UBS holds a more bullish €52 target. The annualised volatility of roughly 34% underscores that Bayer remains a high-beta bet on the outcome of its US legal strategy.
Personnel changes are also on the horizon. Dr. Jost Reinhard will take over the radiology business on August 1, 2026, replacing Nelson Ambrogio. Jana Marlen Ackermann is stepping in as the new head of investor relations, tasked with sharpening the company's communication on capital markets. Investors hope her arrival will lead to a more transparent articulation of Bayer's underlying value as it navigates the twin uncertainties of the Roundup settlement and the Supreme Court's impending ruling.
Ad
Bayer Stock: New Analysis - 20 June
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
